Psilocybin Microdosing on Cognition, Mood and Quality of Life

Starting soon · Early Phase 1 · Has a placebo group

Conditions studied: Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI

In brief

This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.

Key facts

Study ID

NCT07449351

Run by

Yale University

People needed

20

Starts

2026-08-10

Expected to finish

2028-04-01

Last updated by the study team

2026-06-23

Who can join

Age: 21 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• No history of psychedelic use
• Able to read, speak, and understand English
• Able and willing to provide written informed consent, and willing to commit to study protocol
• Women of childbearing potential must be on a highly effective birth control method

You may not qualify if…

• Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment
• Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V
• Current or past alcohol or substance use disorder per DSM-V
• IQ <70 on the Weschler Abbreviated Scale of Intelligence
• Serious medical, neuro-ophthalmological, or neurological illness (e.g., cancer, seizure disorders, encephalopathy)
• Current pregnancy, breastfeeding, or ineffective birth control methods
• History of head trauma with loss of consciousness lasting >30 minutes or concussion in last 30 days
• Any medical/neurological condition that could compromise neurocognitive performance (e.g., epilepsy, multiple sclerosis, fetal alcohol syndrome)
• Anyone deemed unsafe to study personnel for any reason; e.g., suicidal ideation
• Focal brain lesion seen on structural MRI
• MRI contraindications (e.g., implanted metallic object, severe claustrophobia)

Where it is running

• Olin Neuropsychiatry Research Center — Hartford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.